TY - JOUR
T1 - Enhancement of basophil histamine release by interleukin-3
T2 - Reduced effect in atopic subjects
AU - Miadonna, A.
AU - Salmaso, C.
AU - Cottini, M.
AU - Milazzo, N.
AU - Tedeschi, A.
PY - 1996
Y1 - 1996
N2 - The inducing and enhancing effects of interleukin-3 (IL-3) on basophil histamine release in patients with respiratory allergy (n = 28) and) and in normal subjects (n = 22) were compared, Leukocyte suspensions, prepared by dextran sedimentation, were stimulated with anti-IgE (1/5000), N-formylmethionyl-leucyl-phenylalanine (FMLP, 1 μM), and IL-3 (0.1-10 ng/ml), and histamine concentration was measured by an automated fluorometric method. A trend toward higher histamine release after challenge with anti-IgE, FMLP, and IL-3 was found in atopic subjects. Preincubation of basophils with IL-3 resulted in a dose-dependent increase of anti-IgE- and FMLP-induced histamine release, with a more marked effect in nonatopic than in atopic subjects. Mean net enhancement of anti-IgE-induced histamine release by 10 ng/ml IL-3 was 2.5 ± 5% in atopic subjects and 29.6 ± 4.2% in nonatopic subjects (P <0.001). The enhancement of FMLP-induced histamine release by IL-3 was 10.3 ± 3.9% in atopic patients and 29 ± 2.4% in nonatopic subjects (P <0.01). In atopic subjects, a negative correlation was found between anti-IgE- or FMLP-induced histamine release and net enhancement by IL-3 (r = -0.45, P <0.02; r = -0.48, P <0.01, respectively). The results of this study indicate that in atopic subjects IgE-mediated histamine release can scarcely be enhanced by a basophil response modifier such as IL-3. It is conceivable that the frequent basophil stimulation in atopic patients leads to a reduced sensitivity to the enhancing effect of IL-3.
AB - The inducing and enhancing effects of interleukin-3 (IL-3) on basophil histamine release in patients with respiratory allergy (n = 28) and) and in normal subjects (n = 22) were compared, Leukocyte suspensions, prepared by dextran sedimentation, were stimulated with anti-IgE (1/5000), N-formylmethionyl-leucyl-phenylalanine (FMLP, 1 μM), and IL-3 (0.1-10 ng/ml), and histamine concentration was measured by an automated fluorometric method. A trend toward higher histamine release after challenge with anti-IgE, FMLP, and IL-3 was found in atopic subjects. Preincubation of basophils with IL-3 resulted in a dose-dependent increase of anti-IgE- and FMLP-induced histamine release, with a more marked effect in nonatopic than in atopic subjects. Mean net enhancement of anti-IgE-induced histamine release by 10 ng/ml IL-3 was 2.5 ± 5% in atopic subjects and 29.6 ± 4.2% in nonatopic subjects (P <0.001). The enhancement of FMLP-induced histamine release by IL-3 was 10.3 ± 3.9% in atopic patients and 29 ± 2.4% in nonatopic subjects (P <0.01). In atopic subjects, a negative correlation was found between anti-IgE- or FMLP-induced histamine release and net enhancement by IL-3 (r = -0.45, P <0.02; r = -0.48, P <0.01, respectively). The results of this study indicate that in atopic subjects IgE-mediated histamine release can scarcely be enhanced by a basophil response modifier such as IL-3. It is conceivable that the frequent basophil stimulation in atopic patients leads to a reduced sensitivity to the enhancing effect of IL-3.
KW - Atopy
KW - Basophils
KW - Histamine release
KW - Interleukin-3
UR - http://www.scopus.com/inward/record.url?scp=0029813930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029813930&partnerID=8YFLogxK
M3 - Article
C2 - 8874655
AN - SCOPUS:0029813930
VL - 51
SP - 525
EP - 531
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
SN - 0105-4538
IS - 8
ER -